Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

home / authors / jeanny-aragon-ching,-md,-inova-schar-cancer-institute

Articles

Bright Future in Advanced Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Sequencing Considerations in mUC after Frontline IO

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Metastatic Bladder Cancer: Progression After Maintenance

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Educating Patients on Maintenance Therapy in mUC

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Changing the Standard of Care in Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Practical Management of AEs in Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Safety Data from JAVELIN Bladder 100

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Increased Survival Outcomes with Switch Maintenance in mUC

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Switch Maintenance Strategy for Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Value of PD-L1 Testing in Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

PD-L1 Expression in Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Current Status of Therapy: Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512